论文部分内容阅读
目的 探讨急性脑梗死患者发病 6～ 12 0h内尿激酶 (UK)静脉溶栓治疗的安全性和有效性。方法 病例按静脉应用UK量分为 4组 ,按时间窗分为 6组 ,在 6个不同时间点以神经功能评分判定疗效。结果 ①病例溶栓治疗后各时间点NFS较治疗前和上一时间点明显增高。②基本治愈和显著进步率 ,研究组明显高于对照组 ,治疗越早疗效越好。③UK≥ 1.5万U kg组较 1.0万U kg组NFS增加明显 ,而前者 3组间差异无显著性。结论 ①急性脑梗死在发病 6～ 12 0h内以UK1.0～ 2 .5万U kg实施静脉溶栓治疗安全、有效。②时间窗短、UK≥ 1.5万U kg者疗效尤著 ,但量效关系并非呈正相关。
Objective To investigate the safety and efficacy of intravenous thrombolytic therapy of urokinase (UK) in patients with acute cerebral infarction within 6-12h. Methods The patients were divided into 4 groups according to the amount of UK, divided into 6 groups according to the time window, and evaluated the neurological function score at 6 different time points. Results ① After treatment with thrombolytic therapy, NFS at each time point was significantly higher than before treatment and at the last time point. ② basic cure and significant progress rate, the study group was significantly higher than the control group, the earlier the treatment the better. ③UK≥15000 U kg group than the10000 U kg group NFS increased significantly, while the former three groups showed no significant difference. Conclusion ① Acute cerebral infarction is safe and effective in the treatment of intravenous thrombolysis with UK 1.0-2.500 U kg within 6-12h. ② short time window, UK ≥ 15 000 U kg particularly effective, but the dose-effect relationship was not positively correlated.